Condition
Multiple Sclerosis Clinical Trials
Studies of multiple sclerosis, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 662B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Trial name
- MSS (NCT06782490)
- Testing
- BMS-986368
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Celgene
Multiple Sclerosis (MS) Primary Progressive
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Trial name
- NCT07067463
- Testing
- Orelabrutinib
- Where
- 76 sites in United States, Bulgaria and 14 more
- Volunteers
- 705 people
- Sponsor
- Zenas BioPharma (USA), LLC
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 69 sites in United States, Australia and 14 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Multiple sclerosis (MS) is a condition in which the immune system damages the brain and spinal cord. Treatments called disease-modifying therapies can reduce inflammation and disease activity.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- REAL-MS (NCT07899502)
- Testing
- Autologous haematopoietic stem cell transplantation (AHSCT), High-efficacy disease-modifying therapy (HE-DMT)
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Multiple Sclerosis
iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis
iConquerMS™ is a research initiative developed by and for people with multiple sclerosis (MS) to contribute their health data and ideas to advance and accelerate research into MS.
- Trial name
- iCMS (NCT02486562)
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Accelerated Cure Project for Multiple Sclerosis
Multiple Sclerosis
Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.
- Trial name
- FEMINISEP (NCT05754593)
- Testing
- Anti-Mullerian hormone (AMH) level, Antral follicle count (AFC), Clinical assessment
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
This clinical research study is investigating whether the EXOPULSE Suit, a wearable device that delivers electrical stimulation, can help improve movement difficulties caused by spasticity in adults with multiple sclerosis (MS).
- Trial name
- EXO-MS (NCT07897760)
- Testing
- Electrostimulation suit
- Where
- 2 sites in United States, Germany
- Volunteers
- 100 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Multiple Sclerosis
Evaluation of the Effect of Mental Imagery Training Combined With Modified Constraint-Induced Movement Therapy in Individuals With Multiple Sclerosis
This study aims to investigate the effects of mental imagery training combined with modified constraint-induced movement therapy in individuals with multiple sclerosis.
- Trial name
- NCT07899411
- Testing
- odified Constraint-Induced Movement Therapy + Mental Imagery Training, Modified Constraint-Induced Movement Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Hacettepe University
Multiple Sclerosis
A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
This study aims to assess the real-world treatment patterns, data from patient reported outcomes, the effectiveness profile of tolebrutinib, and health care utilization data in routine practice.
- Trial name
- ORION (NCT07898371)
- Testing
- Tolebrutinib
- Where
- United Arab Emirates
- Volunteers
- 3,000 people
- Sponsor
- Sanofi
Completed, with results posted
All 482Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and…
- Trial name
- NCT04144257
- Testing
- [F-18]PBR06, [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Multiple Sclerosis
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e.
- Trial name
- NCT03599245
- Testing
- Ocrelizumab
- Where
- 161 sites in Argentina, Belgium and 24 more
- Volunteers
- 1,055 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Sclerosis
Aerobic Exercise for Remyelination in Multiple Sclerosis
This is a clinical trial to determine the feasibility of a stationary aerobic cycling intervention and explore if aerobic exercise independently promotes remyelination in people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System
- Trial name
- NCT04539002
- Testing
- Aerobic exercise, Education Group Control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Epilepsy, Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- ELEKTRA (NCT03650452)
- Testing
- TAK-935
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 141 people
- Sponsor
- Takeda